Navigation Links
Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
Date:8/5/2013

SAN DIEGO, Aug. 5, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced CEO Mark L. Baum will present at the Southern California Investor Conference on August 8, 2013 at the Island Hotel in Newport Beach, CA. The Imprimis presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT. in Room 2.

About Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a specialty pharmaceutical company focused on the commercial development of drug formulations utilizing the FDA 505(b)(2) drug development pathway. Through its exclusive strategic relationship with the largest compounding pharmacy organization in North America as well as through a growing network of commercial development relationships with pharmacists and physicians across the United States, Imprimis expects to use proprietary drug delivery technologies, proven drug formulations and proprietary market data to identify and pursue pharmaceutical development opportunities where there is a significant unmet medical need.  Imprimis' most near term drug candidate, Impracor, is a Phase III product candidate that utilizes its patented Accudel topical cream formulation to deliver the active drug ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. For more information, visit http://imprimispharma.com/

Contact: Josh Berg
Imprimis Pharmaceuticals, Inc.
(858) 704 4041


'/>"/>
SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
2. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
3. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
4. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
5. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
6. Imprimis Announces Key Leadership Appointments
7. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
8. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
9. Imprimis to Begin New Study of Its Topical Analgesic Drug
10. Imprimis Names Two Experts To Its Science And Regulatory Board
11. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 Een app die artsen ... collectief patiënten kunnen behandelen, hun kennis kunnen delen en ... de nieuwe en revolutionaire MDLinking App, ontwikkeld door een ... dr. Hans Flu en oncologisch chirurg dr. Gijs ... is, wordt op dinsdag 24 mei officieel gepresenteerd op ...
(Date:5/23/2016)... 23, 2016 According to ... Development, Growth and Demand Forecast to 2022 - ... by Application (Drug Discovery and Development, Proteomics, Clinical ... Life Science and Biotechnology, Academic and Research Institute, ... the global mass spectrometry market was ...
(Date:5/23/2016)... , May 23, 2016 Gamida ... the treatment of cancer and orphan genetic diseases, announced ... to $4.4 million from the Israel Innovation Authority (formerly ... Ministry of Economy and Industry. The mission of the ... in various industries, including science and technology, while stimulating ...
Breaking Medicine Technology:
(Date:5/24/2016)... , ... May 24, 2016 , ... Sterling Global Products ... a unique and patented refillable hanging wipe dispenser. The campaign kick-off video is located ... will end June 25, 2016. The goal is to raise $1,000 per day for ...
(Date:5/24/2016)... IL (PRWEB) , ... May 24, 2016 , ... To ... created a new research award to examine gender differences in lung cancer. Today, the ... Research Innovation Project: Lung Cancer in Women Award, funded by the American Lung Association’s ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... debuted a new corporate identity and website at its “Transforming Outcomes” User Conference ... other marketing enhancements reflect i2i’s ongoing success to set the market standard for ...
(Date:5/24/2016)... (PRWEB) , ... May 24, ... ... nationwide provider of communication enabled solutions and managed services today announced a ... for the enterprise contact center market. , Altura, one of Avaya’s largest ...
(Date:5/24/2016)... Falls Church, VA (PRWEB) , ... May 24, 2016 , ... ... June 14-15, 2016 · Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known ... it is unlikely that human error will ever be totally eliminated, many human performance ...
Breaking Medicine News(10 mins):